CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended March 31, 2012. Vertex reported total first quarter 2012 revenues of approximately $439 million, including net product revenues of approximately $357 million from INCIVEK® (telaprevir) and approximately $18 million from KALYDECOTM (ivacaftor). Royalty revenues related to the sale of INCIVO® in Europe by our collaborator were approximately $33 million. The company reported GAAP net income of approximately $92 million and non-GAAP net income of approximately $119 million, or $0.43 and $0.55 per diluted share, respectively. Additionally, Vertex today announced that it expects to obtain data from multiple ongoing clinical trials beginning in the second quarter, including data from a Phase 2 study evaluating KALYDECO in combination with VX-809 in people with the most common type of cystic fibrosis (CF) and the first viral kinetic data of the nucleotide hepatitis C virus (HCV) polymerase inhibitors ALS-2220 and ALS-2158.
